Showing results (501-510 of 753) with videos related to
Sort By:
Pageof 76
Neuro-Oncology|October 15, 2014
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)Patrick Y Wen, Timothy F Cloughesy, Benjamin M Ellingson, et al.Neuro-Oncology|January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survivalBenjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.Neuro-Oncology|June 19, 2008
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor ConsortiumSusan M Chang, Kathleen R Lamborn, John G Kuhn, et al.Blood|September 29, 2018
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphomaHan W Tun, Patrick B Johnston, Lisa M DeAngelis, et al.Cancer Research|May 18, 2017
Targetable T-type Calcium Channels Drive GlioblastomaYing Zhang, Nichola Cruickshanks, Fang Yuan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcomePatrick G Morris, Denise D Correa, Joachim Yahalom, et al.Cancer|July 11, 2019
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872Evanthia Galanis, S Keith Anderson, Erin L Twohy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with afliberceptJohn F de Groot, Yuji Piao, Hai Tran, et al.The Lancet. Oncology|August 21, 2020
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trialVivek Subbiah, Ulrik Lassen, Elena Élez, et al.Cancer Medicine|August 25, 2019
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastomaEudocia Q Lee, Alona Muzikansky, Dan G Duda, et al.Pageof 76